z-logo
open-access-imgOpen Access
Combined chemotherapy and irradiation in anaplastic thyroid carcinoma
Author(s) -
Ivica Pejčić,
Svetislav Vrbić,
Mirjana Scekic
Publication year - 2003
Publication title -
archive of oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.104
H-Index - 13
eISSN - 1450-9520
pISSN - 0354-7310
DOI - 10.2298/aoo0303187p
Subject(s) - medicine , chemotherapy , anaplastic carcinoma , radiation therapy , neutropenia , anaplastic thyroid cancer , thyroid carcinoma , surgery , cisplatin , thyroid cancer , thyroid
Background: Anaplastic thyroid carcinoma (ATC) is a very rare and extremely aggressive cancer; patient's death usually occurs rapidly after diagnosis with a mean survival of six months in the majority of individual research series. Treatment of ATC ranges from surgery, radiotherapy, chemotherapy, or a combination of these regimes. Yet, the optimal sequence of treatment modalities has not been established. Methods: From 1997 to 2002 six consecutive patients with a histological diagnosis of ATC were treated with combined chemotherapy and irradiation at our Clinic for Oncology, Clinical Center Ni¹. Five of these patients were females and 1 male, aged between 28 and 71 years (mean age: 57 years). None of them had distant metastases at the time of diagnosis. Extrathyroidal extension was present in 3 patients with invasion into skin and hypoderm. Treatment consisted of doxorubicin 60 mg/m 2 plus cisplatin 60 mg/m 2 every three weeks. Total doses ranged between 158-375 mg/m 2 for doxorubicin and 183-380 mg/m 2 for cisplatin. External beam radiation to the neck was administered, at a daily dose of 1.2 Gy, up to total doses ranging between 45-60 Gy. Results: One patient achieved a complete response (CR) and one patient achieved a partial response (PR). Three patients had stable disease. One patient with CR progressed during follow-up and died 18 months from bone and brain metastases. The treatment was moderately well tolerated, although all patients experienced some mild form of toxicity; neutropenia occurred in all patients, but none of them required hospital admission. Median survival was 8 months (range: 4-18 months). Conclusion: We concluded that the present regimen produces meaningful responses for patients with localized ATC. A randomized study is needed to determine the effect on survival

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here